Sitemap - 2026 - Thoughts on Healthcare Markets & Technology

Why Healthcare Public-Data Startups Win on the Adjudicated Entity Graph & Not the Thousand Scrapers: Ownership, Fraud, Rollup, and Distress Intelligence for Hospice, Behavioral Health, and Post-Acute

How Children Learn Once You Subtract Language: Statistical Learning, Causal Intervention, Curiosity, and Few-Shot Priors as Buildable Healthcare AI Point Solutions Rather Than One Giant World Model

Part II: How Children Learn Once You Subtract Language: Statistical Learning, Causal Intervention, Curiosity & Buildable Healthcare AI Point Solutions Rather Than One Giant World Model

Part I: How Children Learn Once You Subtract Language: Statistical Learning, Causal Intervention, Curiosity & Buildable Healthcare AI Point Solutions Rather Than One Giant World Model

The 2026 Medicare Trustees Report, Decoded: a 2033 Part A Cliff, a $4.2T Hospital Insurance Hole, GLP-1 & Skin-Substitute Sticker Shock & the 9th Straight Funding Warning Nobody Plans to Fix

A Reasoning Model Reread 376 Unsolved Rare Disease Genomes at Boston Children’s & Surfaced 18 New Diagnoses: What the 4.8% Yield Means, and Why the Real Prize Is Reanalysis as Standing Infrastructure

How Midjourney’s 60-second full-body ultrasound scanner became a LinkedIn fever dream & what the Butterfly chip deal, the wellness-lane FDA play & overdiagnosis math tell healthcare investors

Part II: How Midjourney’s 60-second full-body ultrasound scanner became a LinkedIn fever dream & what the Butterfly chip deal, the wellness-lane FDA play & overdiagnosis math tell healthcare investors

Part I: How Midjourney’s 60-second full-body ultrasound scanner became a LinkedIn fever dream & what the Butterfly chip deal, the wellness-lane FDA play & overdiagnosis math tell healthcare investors

How Optum’s Claims Editing System Got So Big the DOJ Forced a Divestiture That Became Lyric, Why Its PPS Pricer Touches Medicare Advantage Facility Claims, and Why Data Plus Distribution Matters

What a Federally Chartered Roll-Up of Every U.S. Hospital Into One Rate-Regulated National System, Anchored by Medicare and Floated Like Conrail or SpaceX

A Fee-Only, Embedded-Expert Alternative to Benefits Consultants: How Self-Insured Employers Can Reclaim Their Own Claims Data, Sidestep Predatory TPA & PBM Contract Terms, and Stop Paying for Conflict

Part II: An Embedded-Expert Alternative to Benefits Consultants: How Self-Insured Employers Can Reclaim Their Own Claims Data, Sidestep Predatory TPA & PBM Contract Terms & Stop Paying for Conflict

Part I: An Embedded-Expert Alternative to Benefits Consultants: How Self-Insured Employers Can Reclaim Their Own Claims Data, Sidestep Predatory TPA & PBM Contract Terms & Stop Paying for Conflict

Carbene Qubits, Hyperpolarized Sugar, and a $55M Bet from Abbott: How NVision and a Handful of Others Are Building Real Quantum Computing for Healthcare, and Why the Whole Story Comes Down to Energy

When the Rockets and the Robots Go Public: What the SpaceX, Anthropic, and OpenAI IPOs Will Do to the Listing Market, and Which Healthcare and Life Sciences Companies Get to Ride the Next Hype Cycle

Part II: When the Rockets and the Robots Go Public: What the SpaceX, Anthropic & OpenAI IPOs Will Do to the Listing Market & Which Health & Life Sciences Companies Get to Ride the Next Hype Cycle

Part I: When the Rockets and the Robots Go Public: What the SpaceX, Anthropic & OpenAI IPOs Will Do to the Listing Market & Which Health & Life Sciences Companies Get to Ride the Next Hype Cycle

Vibe Coding Against the Fifty Billion Dollar Rural Health Transformation Money: Business Plans From Spend Reporting and Program Integrity to Tele Coverage and Credentialing Rails

How Tampa General & Palantir Built a Sepsis Detection System That Saved 886 Lives

Part II: How Tampa General & Palantir Built a Sepsis Detection System That Saved 886 Lives

Part I: How Tampa General & Palantir Built a Sepsis Detection System That Saved 886 Lives

Why a Startup Just Gave Away Four Million Living Human Neurons for Free: Crownlands, Olfactory Cells, CZ CELLxGENE, and the Open Data Land Grab Reshaping Alzheimer’s Drug Discovery and AI Biology

Healthcare Employs 1 in 9 American Workers, Anthropic Just Published a Plan for AI Wiping Out the Back Office & VC Is Quietly Building the Machinery That Decides Who Gets Redeployed

Part II: Healthcare Employs 1 in 9 American Workers, Anthropic Just Published a Plan for AI Wiping Out the Back Office & VC Is Quietly Building the Machinery That Decides Who Gets Redeployed

Part I: Healthcare Employs 1 in 9 American Workers, Anthropic Just Published a Plan for AI Wiping Out the Back Office & VC Is Quietly Building the Machinery That Decides Who Gets Redeployed

Claude Fable 5 Quietly Routes Biology & Chemistry Prompts to an Older Model & What That Safety Lockdown Means for the Cost, Access & Competitive Map of AI Drug Discovery for Pharma, Biotech & Venture

Building a Medicaid Community Engagement Verification Engine in Claude Code & Selling It to State Agencies Before the January 2027 Deadline: A Field Guide to the Land Grab Behind CMS-2454

Part II: Building a Medicaid Community Engagement Verification Engine in Claude Code & Selling It to State Agencies Before the January 2027 Deadline: A Field Guide to the Land Grab Behind CMS-2454

Part I: Building a Medicaid Community Engagement Verification Engine in Claude Code & Selling It to State Agencies Before the January 2027 Deadline: A Field Guide to the Land Grab Behind CMS-2454

How the Coinbase Founder’s $3.1B Longevity Biotech NewLimit Chose the Most Boring Path in Medicine. What That Means for Peptide & Wellness Bros Dragging Cutting-Edge Longevity Into Reimbursed Health

How the Coinbase Founder’s $3.1B Longevity Biotech NewLimit Chose the Most Boring Path in Medicine.What That Means for Peptide & Wellness Bros Dragging Cutting-Edge Longevity Into Reimbursed Health

Lassie’s $47M a16z Round And The Bet That Autonomous AI Can Replace The Dental Front Desk: Why Sitting In A Back Office Posting 837D Claims By Hand Became A Service-As-Software Wedge Into Health Admin

How the Trump Administration and a Cohort of AI Startups Are Building a Regulatory On-Ramp for Autonomous AI Doctors, and Why Working Physicians Think the Genie Is Already Out of the Bottle

Part II: How the Trump Administration and a Cohort of AI Startups Are Building a Regulatory On-Ramp for Autonomous AI Doctors, and Why Working Physicians Think the Genie Is Already Out of the Bottle

Part I: How the Trump Administration and a Cohort of AI Startups Are Building a Regulatory On-Ramp for Autonomous AI Doctors, and Why Working Physicians Think the Genie Is Already Out of the Bottle

How FDA’s June 2026 Draft Guidance Lets Genome Editing Sponsors Reuse CMC, Nonclinical, Bioinformatics, and Clinical Data Across Programs, and Where the Agency Still Wants Product Specific Work Done

Mayo Owns the Model, Microsoft Owns the Pipes: What the Mayo Clinic and Microsoft Frontier Healthcare AI Deal Reveals

Part II: Mayo Owns the Model, Microsoft Owns the Pipes: What the Mayo Clinic and Microsoft Frontier Healthcare AI Deal Reveals

Part I: Mayo Owns the Model, Microsoft Owns the Pipes: What the Mayo Clinic and Microsoft Frontier Healthcare AI Deal Reveals

Why ASCO Stood Up for Daraxonrasib: RASolute 302, Pancreatic Cancer Survival, and the New KRAS Investment Thesis

Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collections

Part II: Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collections Work

Part I: Inside the Agentic Back Office Race for Specialty Practices: How a YC Company Hit 17x Growth and Seven Figures in ARR by Doing the Fax, Referral, Scheduling, and Collections

Token Economics Versus the 20 Watt Brain: Why Inference Costs, Not Intelligence, Will Cap Clinical AI, & Whose Job It Is to Decide If Machines Should Diagnose Us When They Reason Better but Cost More

A Solopreneur Business Plan for Building Medicaid Fraud Detection Software Aimed at the Early Intensive Developmental and Behavioral Intervention Autism Scam

Part II: A Solopreneur Business Plan for Building Medicaid Fraud Detection Software Aimed at the Early Intensive Developmental and Behavioral Intervention Autism Scam

Part I: A Solopreneur Business Plan for Building Medicaid Fraud Detection Software Aimed at the Early Intensive Developmental and Behavioral Intervention Autism Scam

The Fifteen Dollar Arbitration: How the Final No Surprises Act IDR Operations Rule Cuts Dispute Fees, Rewires Provider & Payer Incentives, and Opens the Door to Arbitration-as-a-Service Business Model

One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.

Part II: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.

Part I: One Infusion. A Permanent Gene Edit. A Lifetime of LDL Lowering. The VERVE-102 NEJM Data, the Lilly Acquisition Thesis, and What It Means.

Mark Cuban’s 10Plan, Then and Now: From the 2019 RAND-Modeled Self-Pay Concept to the 2026 Bank Account Reboot, and What It Would Actually Mean for Insurers and the ACA Risk Pool

How The Joint Commission & CHAI Are Quietly Building A Parallel FDA For Hospital AI & Why The Governance Infrastructure Layer Will Eat More Of The Health AI Market Than The Models Themselves

Part II: How The Joint Commission & CHAI Are Quietly Building A Parallel FDA For Hospital AI & Why The Governance Infrastructure Layer Will Eat More Of The Health AI Market Than The Models Themselves

Part I: How The Joint Commission & CHAI Are Quietly Building A Parallel FDA For Hospital AI & Why The Governance Infrastructure Layer Will Eat More Of The Health AI Market Than The Models Themselves

How DOGE Open Sourcing the T-MSIS Medicaid Spend File Unleashed a Distributed Internet Fraud Hunt That Outran Fed Program Integrity, What the Sleuths Found & What Commercial Payers Could Build

HHS Goes All-In on ChatGPT for State Audits: What the May 2026 Generative AI Fraud Expansion and February’s CRUSH RFI Mean for Payment Integrity, Provider Audit Defense, and the Health Tech Buy-Side

Part II: HHS Goes All-In on ChatGPT for State Audits: What the May 2026 Generative AI Fraud Expansion & Feb’s CRUSH RFI Mean for Payment Integrity, Provider Audit Defense & the Health Tech Buy-Side

Part I: HHS Goes All-In on ChatGPT for State Audits: What the May 2026 Generative AI Fraud Expansion & Feb’s CRUSH RFI Mean for Payment Integrity, Provider Audit Defense & the Health Tech Buy-Side

Eli Lilly’s triple agonist retatrutide hits 28.3% mean weight loss in TRIUMPH-1 phase 3, blowing past tirzepatide benchmarks & rewriting obesity math for payers, PBMs & the Lilly Novo Duopoly

Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaS

Part II: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaS

Part I: Forus Just Raised $160M at a $1B Valuation to Become the Operational Routing Layer for Specialty Rx & the Real Story Is Why Investors Now Believe Healthcare Orchestration Beats SaaS

CMS-2449-P recasts Medicaid State Directed Payments & FFS targeted practitioner supplements @ the Medicare benchmark, kills the ACR ceiling, bans uniform increases & projects $774.8B in 10yr savings

RN, NP, and PA Pay by State Adjusted for Cost of Living Using BLS May 2024 Data: Why CA Headline Crown Is a Mirage, Why OK and IN Quietly Win, and What It Means for Workforce Strategy in 2025

Part II: RN, NP, and PA Pay by State Adjusted for Cost of Living Using BLS May 2024 Data: Why CA Headline Crown Is a Mirage, Why OK and IN Quietly Win, and What It Means for Workforce Strategy in 2025

Part I: RN, NP, and PA Pay by State Adjusted for Cost of Living Using BLS May 2024 Data: Why CA Headline Crown Is a Mirage, Why OK and IN Quietly Win, and What It Means for Workforce Strategy in 2025

Cuban Joins Trump at TrumpRx to Add 600 Generics via Cost Plus, Amazon, GoodRx: Why Cash Pricing That Skips Deductibles Misses Most Insured Americans & How PBM Formulary Threats Block Brand Adoption

Hardware Hits Mega-Round Season Again: Whoop’s $575M at $10.1B, Neuralink at $9.7B, BrainCo’s $1.3B Unicorn Birth, eMed’s $200M Series A at $2B, and Whether Consumer Hardware Is Back

Part II: Hardware Hits Mega-Round Season Again: Whoop’s $575M at $10.1B, Neuralink at $9.7B, BrainCo’s $1.3B Unicorn Birth, eMed’s $200M Series A at $2B, and Whether Consumer Hardware Is Back

Part I: Hardware Hits Mega-Round Season Again: Whoop’s $575M at $10.1B, Neuralink at $9.7B, BrainCo’s $1.3B Unicorn Birth, eMed’s $200M Series A at $2B, and Whether Consumer Hardware Is Back

What contracting with Epic for an EHR license really involves: license structure, module pricing, affiliate rights, hosting, termination economics, and the unwritten obligations behind the signature

How the Final 2027 NBPP Reshapes the ACA Individual Market: Business Models Emerging From Non-Network QHPs, Decade-Long Catastrophic Plans, Direct Enrollment Distribution, and the EHB Defrayal Shift

How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject Home Health Fraud at Submission and Break the Decade-Long Federal Moratorium Loop

Part II: How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject Home Health Fraud at Submission and Break the Decade-Long Federal Moratorium Loop

Part I: How Geotagged EVV Check-In Data Can Get Wired Into Medicaid and Medicare Managed Care Claim Edits to Reject Home Health Fraud at Submission and Break the Decade-Long Federal Moratorium Loop

Isomorphic Labs Pulls $2.1B Series B Led By Thrive With MGX, Temasek, And UK Sovereign AI Fund: What The Capital Stack, IsoDDE Engine, And Novartis/Lilly/J&J Partnerships Mean For Drug Discovery

Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene, & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits & Tighter Utilization Mgmt

Part II: Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits & Tighter Utilization Mgmt

Part I: Why The Q1 2026 Payer Margin Rebound At UnitedHealth, CVS, Elevance, Humana, Centene & Molina Is Really A Benefit Design Recession Built On Repricing, Product Exits, & Tighter Utilization Mgmt

The Hidden Rule Makers Behind Prior Auth and Claim Denials: How InterQual, MCG, HealthEdge, Zelis, Lyric, and Optum’s CES Write the Criteria Payers Use to Reject Care and Why That’s Where Real Reform

What the Six Hundred Billion Dollar MFN Headline Misses: The Best Price Carveout, the IQVIA Net Price Hole, and the CMMI BALANCE Workaround That Makes Trump’s Drug Pricing Framework Run

Part II: What the Six Hundred Billion Dollar MFN Headline Misses: The Best Price Carveout, the IQVIA Net Price Hole, and the CMMI BALANCE Workaround That Makes Trump’s Drug Pricing Framework Run

Part I: What the Six Hundred Billion Dollar MFN Headline Misses: The Best Price Carveout, the IQVIA Net Price Hole, and the CMMI BALANCE Workaround That Makes Trump’s Drug Pricing Framework Run

Gene Editing Has the Science Figured Out and Now Needs an Entire Stack of New Business Models, Reimbursement Mechanics, and Healthcare Operating Infrastructure Before Any of This Scales to Patients

What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days

Part II: What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days

Part I: What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days

The Peptide Split: How GLP-1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC-157, TB-500, MOTS-c, and the Wellness Grift Borrow Their Halo

Reading OpenAI’s Keeping Patients First Blueprint: What the April 2026 Healthcare Policy Document Proposes on Data Portability, Information Blocking, Regulatory Sandboxes, and FDA Modernization

The OpenAI Anthropic AI Arms Race Pivoted From Models To Services & Deployment. And Healthcare Is The Stress Test.

Part II: The OpenAI Anthropic Arms Race Pivoted From Models To Services & Deployment. And Why Healthcare Is The Stress Test.

Part I: The OpenAI Anthropic Arms Race Pivoted From Models To Services & Deployment. And Why Healthcare Is The Stress Test.

Part II: What the Harvard ER Study Says About o1 Beating Doctors at Diagnosis, Why It Means Differential Diagnosis Just Stopped Being a Scarce Cognitive Asset, and Where the Money Goes Next

Part I: What the Harvard ER Study Says About o1 Beating Doctors at Diagnosis, Why It Means Differential Diagnosis Just Stopped Being a Scarce Cognitive Asset, and Where the Money Goes Next

What the Harvard ER Study Says About o1 Beating Doctors at Diagnosis, Why It Means Differential Diagnosis Just Stopped Being a Scarce Cognitive Asset, and Where the Money Goes Next

Part II: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need

Part I: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Need

Part II: The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD and the Pre-Diagnostic Pancreas Force a Rethink of Cancer Screening Math, Workflow Economics, and the Multimodal Future of Risk Inference

Part I: The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD and the Pre-Diagnostic Pancreas Force a Rethink of Cancer Screening Math, Workflow Economics, and the Multimodal Future of Risk Inference

The FDA Real Time Clinical Trial Announcement Quietly Dissolves Phase Gates, Breaks Biotech Capital Markets Plumbing, and Opens a Founder Sized Hole in Trial Infrastructure, Financing, and Workflow

Profluent's $2.25B Lilly Deal and Why Treating Proteins as a Language Modeling Problem Is a Bigger Story Than the Headline Suggests: Scaling Laws, Synthetic Biology, and the Compute Substrate Thesis

How AI, Value Based Care Bundles, Medicare Payment Compression, and IMG-Driven Residency Match Dynamics Will Reshuffle the Wealthiest Physician Specialty Rankings Over the Next Five to Ten Years

The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven't Noticed Yet: The Plausible Mechanism Framework and NGS Safety Guidance That Could Reshape Rare Disease Investment

CMS-0062-P Deep Dive: What the 2026 Interoperability and Prior Authorization for Drugs Proposed Rule Actually Means for Health Tech Investors and Entrepreneurs

The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the Compounding Pharmacy Stack, GLP-1 Gray Market, and Longevity Clinic Supply Chain

Amazon Bio Discovery: What AWS Just Launched, Why It Actually Matters for Drug Development, and What Health Tech Investors Need to Understand About the Platform War Now Playing Out in Life Sciences

Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shape

GPT-Rosalind Lands: What OpenAI's First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually Mean

The CMS national provider directory: a complete analysis of 27.2 million healthcare records in the entrepreneurial opportunity that they represent

Bundles Are Back, Now Mandatory and Nationwide: A Builder's Field Guide to the New Companies, Tools, and Channels That Should Get Built Around CMS's CJR-X Lower-Extremity Joint Replacement Model

How Late 2025 and Early 2026 Earnings Calls Expose the Medicare Advantage Pullback, the Migration of Margin From Insurance to Services, and the Quiet Redistribution of Healthcare Profit Pools

The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Read

How Commercial Insurers, Self-Insured Employers, PBMs, and Manufacturers Are Turning GLP-1 Pharmacy Benefits Into Active Managed-Access Operating Systems and Where the Infrastructure Opportunity Sits

The Prior Auth API Economy: How CMS-0057-F, CMS-0062-P, Da Vinci FHIR Rails, State Gold Carding Laws, AI Guardrails, and the AHIP/BCBSA 257M Commitment Turn UM Into a Programmable Transaction

Start Here: How to Get the Most Out of This Newsletter

Programmable Medical Necessity & the Pricing Computation Layer: How Prior Auth API Infrastructure, Claims-Derived Transparency Data, and ERISA Fiduciary Litigation Are Rewiring Commercial Healthcare

The BALANCE Model Pause, the GLP-1 Bridge Extension Thru Dec 2027 & What the 80% Part D Participation Threshold Miss Signals About Medicare's First Real Attempt to Negotiate Anti-Obesity Drug Coverage

The CMS-FDA RAPID Coverage Pathway Is a Capital Markets Event Disguised as a Coverage Policy: What the Regulatory-Reimbursement Clock Synch Means for Medtech Investment & Device Commercialization

What does 17 pharma MFN deals are underneath the press releases: the real primary source stack, the GLP1 numbers, TrumpRX plumbing, and where the new adjudication layer gets monetized

Commercial Value-Based Care Has Quietly Turned Into a Real Messy, Multi-Payer Operating Layer Wedged Btwn Employer Cost Pressure, Payer Network Strategy, Specialty Economics & Provider Margin Reality

Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shape

What Judy Faulkner’s Freakonomics interview tells us about Epic’s Ten Commandments, the Purpose Trust succession, the 30 percent R&D rate, and the live antitrust fight in healthcare

FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide — Part II

The On Healthcare podcast is now live on Spotify and Apple Podcasts.

The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD Forces a Rethink of Cancer Screening Math — Part II

The Fifty Billion Dollar Rural Health Wager — Part II

The FDA Real Time Clinical Trial Announcement Quietly Dissolves Phase Gates, Breaks Biotech Capital Markets Plumbing, and Opens a Founder Sized Hole in Trial Infrastructure, Financing, and Workflow

Profluent’s $2.25B Lilly Deal and Why Treating Proteins as a Language Modeling Problem Is a Bigger Story Than the Headline Suggests: Scaling Laws, Synthetic Biology, and the Compute Substrate Thesis

Lilly paid $2.25B for a company that treats biology like a language model.

How AI, Value Based Care Bundles, Medicare Payment Compression, and IMG-Driven Residency Match Dynamics Will Reshuffle the Wealthiest Physician Specialty Rankings Over the Next Five to Ten Years

When $Hims Lost Its Moat

A Public Equity Diligence Walk on HIMS After the GLP-1 Reset, the Eucalyptus Buy, and the Peptide Catalyst: What the FY2025 10-K, Novo Settlement, and LillyDirect Routing Tell You Heading Into Q1 2026

Where Commercial VBC Actually Lives Now

Commercial Value-Based Care Has Quietly Turned Into a Real Messy, Multi-Payer Operating Layer Wedged Btwn Employer Cost Pressure, Payer Network Strategy, Specialty Economics & Provider Margin Reality

Decoding the CMS Access Model: Half Your Revenue Lives in Escrow

What does 17 pharma MFN deals are underneath the press releases: the real primary source stack, the GLP1 numbers, TrumpRX plumbing, and where the new adjudication layer gets monetized

The CMS-FDA RAPID Coverage Pathway Is a Capital Markets Event Disguised as a Coverage Policy: What the Regulatory-Reimbursement Clock Synch Means for Medtech Investment & Device Commercialization

The BALANCE Model Pause, the GLP-1 Bridge Extension Thru Dec 2027 & What the 80% Part D Participation Threshold Miss Signals About Medicare’s First Real Attempt to Negotiate Anti-Obesity Drug Coverage

Programmable Medical Necessity & the Pricing Computation Layer: How Prior Auth API Infrastructure, Claims-Derived Transparency Data, and ERISA Fiduciary Litigation Are Rewiring Commercial Healthcare

Start Here: How to Get the Most Out of This Newsletter

The Prior Auth API Economy: How CMS-0057-F, CMS-0062-P, Da Vinci FHIR Rails, State Gold Carding Laws, AI Guardrails, and the AHIP/BCBSA 257M Commitment Turn UM Into a Programmable Transaction

How Commercial Insurers, Self-Insured Employers, PBMs, and Manufacturers Are Turning GLP-1 Pharmacy Benefits Into Active Managed-Access Operating Systems and Where the Infrastructure Opportunity Sits

The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Read

How Late 2025 and Early 2026 Earnings Calls Expose the Medicare Advantage Pullback, the Migration of Margin From Insurance to Services, and the Quiet Redistribution of Healthcare Profit Pools

Bundles Are Back, Now Mandatory and Nationwide: A Builder’s Field Guide to the New Companies, Tools, and Channels That Should Get Built Around CMS’s CJR-X Lower-Extremity Joint Replacement Model

The CMS national provider directory: a complete analysis of 27.2 million healthcare records in the entrepreneurial opportunity that they represent

GPT-Rosalind Lands: What OpenAI’s First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually Mean

Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shape

Amazon Bio Discovery: What AWS Just Launched, Why It Actually Matters for Drug Development, and What Health Tech Investors Need to Understand About the Platform War Now Playing Out in Life Sciences

The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the Compounding Pharmacy Stack, GLP-1 Gray Market, and Longevity Clinic Supply Chain

CMS-0062-P Deep Dive: What the 2026 Interoperability and Prior Authorization for Drugs Proposed Rule Actually Means for Health Tech Investors and Entrepreneurs

The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven’t Noticed Yet: The Plausible Mechanism Framework and NGS Safety Guidance That Could Reshape Rare Disease Investment

A Blunt Assessment of Every Major ACCESS Model Participant, Their Business Models, and What CMS’s New Outcome-Aligned Payment Framework Actually Means for Their P&L and Patient Populations

Prior Auth & Denials Are Healthcare’s Most Hated Processes But Medicare and Medicaid Lose $100-300B a Year to Fraud While Commercial Plans Lose 1-3% and the Difference Is Largely That Commercial Plan

How Claude Mythos Preview Found Thousands of Zero-Day Vulnerabilities and Why the Health Tech Sector’s Absence From Project Glasswing Should Alarm Every Investor and Entrepreneur in the Space

The PCP as Specialist: How AI and Virtual Consults Will Collapse the Referral Economy and Create a New Category of Primary Care Company

AbbVie Just Filed the Most Important 340B Lawsuit Nobody Saw Coming

NVIDIA Just Helped Map 31 Million Protein Complexes and the Health Tech Investment Implications Are Enormous

From Fringe to Formulary: How Integrative Medicine, Peptides, and the D2C Biomarker Stack Are Reshaping the Boundaries of Evidence-Based Care

The BALANCE Model, GLP-1 Coverage, and the Peptide Regulatory Collision: What Every Health Tech Operator and Investor Needs to Know Right Now

The CY 2027 MA Rate Announcement as an Entrepreneur’s Prospectus

Yuzu Health, General Catalyst, and the Quiet Bet on Health Insurance Plumbing

The Peptide Economy vs the Healthcare AI Economy: Which Side of the Trade Matters More

The hospice industries fraud crisis just got a reckoning: reading the FY 2027 CMS proposed rule against the backdrop of operation never say die

The CY2027 MA and Part D Final Rule: What Actually Matters for Health Tech Investors

The $1.8B Ozempic Middleman and What It Actually Means for Health Tech

What the leaked Claude Code codebase tells healthcare builders about designing agentic health tech

Clinical Trials Are the New Bottleneck: AI Drug Discovery Has Created an Evidence Infrastructure Crisis

NVIDIA’s Healthcare Stack Is the Picks and Shovels Play You’ve Been Waiting For

b.well Connected Health: The $120M Infrastructure Play Quietly Powering Every Major Health AI Launch of 2026

The Unfair Advantage Nobody Talks About: How Skipping BAAs Unlocks Venture-Scale Growth in Health Tech

The MATCH Monopoly and What It Actually Means for Health Tech

The CMS advisory committee drop: 18 people, one agenda, and a bunch of subtext

The YC W26 health tech field notes: what 22 companies at demo day tell us about where healthcare AI is actually going

$125M and a Cap Table That Reads Like a Who’s Who of Healthcare VC: What Qualified Health’s Series B Actually Signals

The 2026 ISA: ONC Drops a Catalog, Founders Should Read It Like a Term Sheet

The Elon Terrawatt Announcement Nobody in Health Tech Is Taking Seriously Enough

The $2.3B Wake-Up Call: What GE HealthCare’s Intelerad Deal Actually Means for Imaging IT

The Fax Machine Died (Again): What CMS-0053-F Means for Health Tech Investors and Builders

Clinical Reasoning vs. Documentation: The Next Battleground for Medical LLMs

How the Government Built a Cage Around Healthcare, One Law at a Time

NemoClaw and the Healthcare Agent Trust Problem

The AI Factory Is Jensen Huang’s Most Important Keynote in a Decade: Implication for Healthcare

HTI-5 and the New Ground Rules for Health Data: What the Comment Letters Actually Say

The 340B Software Stack: The Next Healthcare SaaS Vertical

The USB-C Port for Healthcare AI: Why MCP Is the Protocol That Actually Matters Right Now

The labor problem healthcare won’t solve with recruiting

Raising capital in health tech when the market has no patience for excuses

The HIMSS Conference Nobody Actually Attended

HIMSS26 Field Notes: The Agentic Turn Is Real and It Happened Fast

Epic’s agent factory and the end of the middle layer: what health tech investors need to understand right now

The Pipes Are Finally Moving: Why Clinical Event Streaming Is the Infrastructure Bet Nobody Took Seriously Enough

Labor Market Disruption from AI in Healthcare: Where the Real Money Is

The Medicare login upgrade nobody’s talking about: why identity infrastructure is the most underrated distribution rail in health tech

The Health System Opportunity Stack: A Builder’s Guide to the Most Underserved Enterprise in America

Regulatory Arbitrage as Investment Strategy: What Frist Cressey Ventures Got Right Before Everyone Else

The Pattern Always Repeats: Why Healthcare’s Next Revolution Runs on Electricity, Not Software

The AI medical services act: what it gets right, where it falls short, and why it matters for the next decade of digital health

The Picks and Shovels of Digital Health: Infrastructure Bets That Will Define the Next Decade

CMS Just Padlocked the Cookie Jar: What the CRUSH Initiative and DMEPOS Moratorium Actually Mean for Health Tech Investors and Entrepreneurs

60 Million Reasons to Pay Attention: The Investment Thesis Behind Chamber Cardio’s Series A

The Free Lunch Is Over, Except Now It’s Not: What Near-Zero Software Costs Mean for Every Player in Healthcare

The AI clinical infrastructure company: why the real money in Health AI isn’t in the models

The Health System Data Monetization Cartel: Why the Most Valuable Dataset in Life Sciences Is Sitting on the Table

Nobody gets sued but the doctor: The legal vacuum at the center of the AI physician revolution

Who’s the Agent? Building the Identity Layer Healthcare AI Actually Needs

The standardization trap: why deploying AI agents in healthcare require requires a Palantir-style approach to “forward deployed” custom workflow engineering

The $145M Federal Subsidy Nobody in Health Tech Is Talking About Yet

The Biologic Volatility Problem and Why Someone Should Build a Hedge Fund for Specialty Drug Risk

The Data Stack That Catches Crooks: Linking Open Datasets to the New Medicaid Spend Data, Why Home Health Is a Fraud Paradise, and How to Build a Business on Top of All of It

The Chatbot in the Courtroom: What U.S. v. Heppner Means for Health Tech Founders Who Use AI to Think Through Legal Problems

Access, OAPs, and the Illusion of Easy Money: A Strategic Guide for Health Tech Investors and Operators

The $800B Open Secret: What the New Medicaid Spending Dataset Means for Health Tech Builders and Investors

OpenClaw in the Clinic: A Business Plan for HIPAA-Compliant Deployment of Agentic AI at Scale in Payer and Provider Organizations

Glass-Steagall for Healthcare: What the Break Up Big Medicine Act Actually Means for Founders and Investors

The ACA’s 2027 Overhaul: What the NBPP Proposed Rule Actually Means for Health Tech Entrepreneurs

Compounding’s Reckoning: What Hims Getting Smacked by FDA Tells Us About Healthcare’s Gray Markets

World models walk into a hospital: why this time it actually matters

Virtual Card Rails Beyond Claims: Where Healthcare Payments Actually Want to Be Automated

The Labor Reallocation Problem: Why Healthcare Productivity Is a Structural GDP Issue and How Task Decomposition Plus Robotics Could Actually Fix It

The Dialysis Progression Prediction Problem: Why Nephrology Practices Will Pay for Better Crystal Balls

The Transparency Crisis: Engineering Solutions for Payer Price Data at Scale

Where Smart Money Should Go in Healthcare Technology Right Now

Deepgram’s healthcare gambit: when the best voice AI isn’t built for healthcare

UnitedHealth’s 2025 Earnings Call: What Health Tech Builders Need to Know About the New Normal

The Accidental Death of Healthcare Administration: How Gamified Price Transparency Could Trigger Systems Collapse

The Interface Wars: Why Apple Spent Two Billion Dollars on Mind Reading Technology and What It Means for Healthcare AI

The Medicaid Tech Pledge: Why 600 Million in Savings Means Almost Nothing for Innovation

The API is the Scalpel: A Business Plan for a Multimodal Health Data Layer

The unglamorous path to a $25m exit: a tactical guide for first time health tech founders who want to actually make money

Fixing organ procurement: a business plan for making OPO performance actually matter

Bessemer’s Health AI Report: What Actually Matters for Operators

The Gold Rush is Over, Now We Sell Shovels

Understanding Healthcare Spending Trends: A Guide to Finding the Next Big Opportunity

Cuban’s healthcare provocation and why the devil lies in the implementation details

Following the money: what healthcare funding battles tell us about where to build

ACCESS Model: The Digital Health Payment Experiment That Might Actually Matter

New margin math: what vizient’s 2026 healthcare trends report means for health tech entrepreneurs

The Coming Collision Between Foundation Models and Regulated Clinical Decision Support

The $231 Million Crisis Tech Opportunity Everyone’s Sleeping On

What tier 1 healthcare VC’s are really buying: a ground level reading of precede seed in series a health tech deals

ACO LEAD Enablement Platform Business Plan and Technical Architecture

Brain-Computer Interfaces in Healthcare: Building the Picks and Shovels Company While the Giants Fight Over Gold

Building for the post transparency economy: Trump’s great healthcare plan

Why Lingshu-7B has 5.5x as many downloads on Hugging Face as the second most downloaded medical AI model

The Coming Audit Economy: How Epic v Health Gorilla Could Birth a New Industry in Healthcare Data Compliance

Test

After after coding: imagining risk adjustment when accuracy breaks the business model

How to build a prior authorization intelligence business without lighting money on fire: how to guide for bootstrappers

The PBM-GPO Unbundling: Why Vertical Integration is Finally Cracking and What Comes Next

Claude’s Path to Healthcare AI Dominance

When State Regulators Became Your Unexpected Co-Investors: The Hidden Economics of Healthcare Transaction Review

The Data Bottleneck: Why Andreessen Horowitz Bet $30M on Protege

The Greatest Regulatory Arbitrage Plays in Healthcare History

ChatGPT Health and Why Foundation Models Still Cannot Crack Healthcare Alone

ONC’s Deregulatory Push: What Health Tech Builders Actually Need to Know About the Proposed Information Blocking Changes

ChatGPT in healthcare: What the numbers tell us about consumer behavior and market opportunity

What Actually Needs Building: Ten Healthcare Companies for 2026

GUARD and GLOBE Walk Into a Spreadsheet: How CMS Accidentally Created the Next Health Tech Infrastructure Cycle

The LEAD Model and the Coming Rebuild of Value-Based Care Plumbing

The longest ACCESS article you’ll ever find: CMS builds a chronic care market where half your money lives in escrow and clinical outcomes to determine whether you ever see it

The New Price Transparency Stack and the Very Investable Plumbing Hiding Inside It

When the shark meets the pediatrician: what the Cuban-Conway debate reveals about healthcare structural problems

Rural Health Transformation Program: Strategic Playbook for Healthcare Startups